key advancements in the treatment of bpdcn from ebmt 2024
Published 5 months ago • 48 plays • Length 1:07Download video MP4
Download video MP3
Similar videos
-
1:42
recent advances & unmet needs in bpdcn
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
2:41
an overview of the latest advances in hematology
-
0:59
the common clinical manifestations of bpdcn
-
1:45
the role of non-covalent btkis in the era of covalent btkis for b-cell malignancies
-
2:03
the current landscape of treatment for bpdcn
-
2:12
novel agents of interest for the treatment of bpdcn
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
-
1:49:33
cbct treatment planning - by randolph r. resnik, dmd, mds
-
2:01
the evolution of bcl2 inhibition in cll
-
1:57
updates on treatment approaches for patients with bpdcn
-
1:41
improvements in the awareness and diagnosis of bpdcn
-
1:22
unmet needs in bpdcn
-
1:12
exciting advances in dlbcl: molecular characterization of subtypes & novel immunotherapeutic agents
-
2:57
novel targeted therapies for the treatment of bpdcn
-
1:09
dec-c plus venetoclax in hr-mds and cmml: an analysis using different response criteria
-
1:08
latest advances in bp-mpns
-
0:47
novel agents being explored for the treatment of immune-mediated ttp
-
1:27
access to therapy for indolent lymphomas in latin america
-
1:44
long-term results from a trial of tag in patients with bpdcn
-
3:23
patient characteristics and outcomes of allosct for bpdcn